NYSE:BLCOMedical Equipment
Assessing Bausch + Lomb (BLCO) Valuation After New Eye Surgery Tools And enVista Envy Lens Launch
Bausch + Lomb (BLCO) is drawing fresh attention after 510(k) clearance for new vitrectomy tools, a European launch for its enVista Envy intraocular lens, and extensive data presentations at the upcoming ASCRS ophthalmology meeting.
See our latest analysis for Bausch + Lomb.
These product updates come as Bausch + Lomb’s share price sits at $16.71, with a 7 day share price return of 4.96% and a 1 year total shareholder return of 40.07%. This suggests recent news is feeding into improving...

